Liminal Biosciences Inc

NASDAQ:LMNL  
4.78
+0.11 (+2.36%)
Products

Liminal BioSciences Provides Update On Progress On BLA For Ryplazim

Published: 09/21/2020 13:24 GMT
Liminal Biosciences Inc (LMNL) - Liminal Biosciences Provides Update on Progress on Bla for Ryplazim®(plasminogen).
Liminal Biosciences - FDA Confirmed That Resubmission is a Complete, Class 2 Response and Has Provided a PDUFA Target Action Date of March 5, 2021.
Liminal Biosciences - FDA Acknowledged Receipt of Resubmission, by Its U.S. Subsidiary, Prometic Biotherapeutics Inc., of Bla for Ryplazim.
Liminal Biosciences - Sees Potential Approval and Commercial Launch of Ryplazim in U.S. in 2021.